| Autor: |
Queiro R; Rheumatology & ISPA Translational Immunology Division, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.; Department of Medicine, Oviedo University School of Medicine, 33011 Oviedo, Spain., Coto P; Dermatology Division, Hospital Vital Alvarez Buylla, 33611 Mieres, Spain., González-Lara L; Dermatology Division, Hôpital Ambroise-Paré, 92100 Boulogne-Billancourt, France., Coto E; Department of Medicine, Oviedo University School of Medicine, 33011 Oviedo, Spain.; Molecular Genetics Unit, Hospital Universitario Central Asturias, 33011 Oviedo, Spain. |
| Abstrakt: |
Psoriasis is a multifactorial genetic disease for which the genetic factors explain about 70% of disease susceptibility. Up to 30-40% of psoriasis patients develop psoriatic arthritis (PsA). However, PsA can be considered as a "disease within a disease", since in most cases psoriasis is already present when joint complaints begin. This has made studies that attempt to unravel the genetic basis for both components of psoriatic disease enormously difficult. Psoriatic disease is also accompanied by a high burden of comorbid conditions, mainly of the cardiometabolic type. It is currently unclear whether these comorbidities and psoriatic disease have a shared genetic basis or not. The nuclear factor of kappa light chain enhancer of activated B cells (NF-κB) is a transcription factor that regulates a plethora of genes in response to infection, inflammation, and a wide variety of stimuli on several cell types. This mini-review is focused on recent findings that highlight the importance of this pathway both in the susceptibility and in the determinism of some features of psoriatic disease. We also briefly review the importance of genetic variants of this pathway as biomarkers of pharmacological response. All the above may help to better understand the etiopathogenesis of this complex entity. |
